A5061515387- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Cancer-related gene regulation
- Cancer Genomics and Diagnostics
- Liver Disease Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Cancer-related Molecular Pathways
- Glycosylation and Glycoproteins Research
- Testicular diseases and treatments
- Esophageal and GI Pathology
- Telomeres, Telomerase, and Senescence
- Cerebrovascular and Carotid Artery Diseases
- Neuroblastoma Research and Treatments
- Chronic Lymphocytic Leukemia Research
Prince of Songkla University
2014-2025
Songklanagarind Hospital
2009-2025
Institute of Cancer Research
2024
Ministry of Education
2024
Goethe University Frankfurt
2024
Harbin Medical University
2024
Cancer Research Institute
2024
University of Hong Kong
2024
Queen Mary University of London
2024
Seoul National University Hospital
2024
Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients non–small-cell lung cancer.
The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) efficacy according to epidermal growth factor receptor (EGFR) biomarker status.In all, 1,217 patients randomly assigned. Biomarkers analyzed EGFR mutation (amplification refractory system; 437 evaluable), gene copy number...
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal signaling. This phase III study assessed the efficacy vandetanib versus erlotinib in unselected patients with advanced non–small-cell lung cancer (NSCLC) after treatment failure one to two prior cytotoxic chemotherapy regimens. Patients Methods One thousand hundred forty were randomly assigned receive 300 mg/d (n = 623) or 150 617). The primary objective was show superiority...
There is an urgent need for first-line treatment options patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric gastroesophageal junction (mG/GEJ) adenocarcinoma. Claudin-18 isoform (CLDN18.2) expressed in normal cells and maintained malignant G/GEJ adenocarcinoma cells. GLOW (closed enrollment), a global, double-blind, phase 3 study, examined zolbetuximab, monoclonal antibody that targets CLDN18.2, plus capecitabine...
BackgroundInavolisib is a highly potent and selective inhibitor of the alpha isoform p110 catalytic subunit phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes degradation mutated p110α. Inavolisib plus palbociclib–fulvestrant has shown synergistic activity in preclinical models promising antitumor early-phase trials.MethodsIn phase 3, double-blind, randomized trial, we compared first-line inavolisib (at an oral dose 9 mg once daily) (inavolisib group) with placebo...
•This article provides ESMO recommendations adapted for the treatment of GC in Asian patients.•It outlines clinical diagnosis, staging, management, and follow-up patients with GC.•Applicability to availability/reimbursement certain tests treatments is described.•The aim encourage evidence-based medicine improve access state-of-the-art cancer care. The European Society Medical Oncology (ESMO) Clinical Practice Guidelines gastric (GC), published late 2022 updated Gastric Cancer Living...
1003 Background: INAVO120 (NCT04191499) showed significantly and meaningfully improved investigator-assessed progression-free survival (PFS; stratified hazard ratio 0.43) with Inavo+Palbo+Fulv v Pbo+Palbo+Fulv, manageable safety tolerability. To further characterize the substantial benefit/risk of Inavo triplet, we assessed additional clinically relevant efficacy endpoints, detailed data key adverse events (AEs) for (hyperglycemia [HG], diarrhea, rash, stomatitis), pt-reported outcomes...
A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).
405736 Background: There is an unmet need for novel targeted therapies that improve outcomes pts with HER2− LA unresectable or mG/GEJ adenocarcinoma. CLDN18.2 expressed in normal gastric mucosa cells and retained most G/GEJ adenocarcinomas. In the phase 3 SPOTLIGHT study, zolbetuximab, a CLDN18.2-targeted chimeric monoclonal antibody, significantly prolonged PFS OS CLDN18.2+/HER2− adenocarcinoma when combined mFOLFOX6. GLOW (NCT03653507) global, double-blind study comparing zolbetuximab PBO...
Highlights•The HIMALAYA study showed improved outcomes with STRIDE vs. sorafenib in unresectable hepatocellular carcinoma (uHCC).•In an Asian subgroup of HIMALAYA, overall survival and objective response rates sorafenib.•Outcomes were the participants enrolled Hong Kong Taiwan.•Treatment-related adverse events generally manageable low grade subgroup.•STRIDE is beneficial for people uHCC Asia-Pacific region, consistent global population.AbstractBackground & AimsIn global, phase III (uHCC),...
250 Background: First-line (1L) pembro + chemo significantly improved survival versus placebo (pbo) in patients (pts) with advanced esophageal cancer after a median follow-up of 22.6 mo the randomized phase 3 KEYNOTE-590 study (NCT03189719). We report 5-yr data. Methods: Eligible pts had locally advanced/metastatic adenocarcinoma or squamous cell carcinoma esophagus (ESCC), Siewert type I gastroesophageal junction adenocarcinoma; measurable disease per RECIST v1.1; and ECOG PS 0 1. Pts were...
8009 Background: Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling. This phase III study compared the efficacy vandetanib vs erlotinib in patients (pts) with advanced, previously treated NSCLC. Methods: Eligible pts (stage IIIB/IV NSCLC, PS 0–2, 1–2 prior chemotherapies; all histologies permitted) were randomized 1:1 to receive 300 mg/day or 150 until progression/toxicity. The primary objective was show superiority progression-free survival (PFS) for erlotinib....
Although the incidence of cancer increases with age, older patients are under-represented in treatment trials, resulting limited data availability this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (<65 vs ≥ 65 years) a randomized, double-blind, placebo-controlled phase III trial HER2-positive metastatic breast cancer. Patients who had not received previous chemotherapy or biological therapy for locally recurrent, unresectable were...
The Phase III, randomized, open-label IPASS study (NCT00322452) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib versus carboplatin/paclitaxel for Asian patients with advanced non-small-cell lung cancer (NSCLC) showed that investigator-assessed progression-free survival (PFS) and objective response rate (ORR) were significantly prolonged in EGFR mutation-positive NSCLC who received mutation-negative NSCLC. We report post-hoc analyses data by blind...
539 Background: Durvalumab plus tremelimumab (Durva/Treme) andatezolizumab bevacizumab are preferable first-line therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the efficacy and safety of Durva/Treme in real world setting. Methods: Fifty patients with uHCC who enrolled expanded access program (EAP) as treatment from 12 centers Thailand were included. Analysis was assessed objective response rate (ORR), survival, adverse events. We also compared data...
Abstract Concurrent chemoradiotherapy (CCRT) induces toxicities from inflammation and immunological suppression. Omega-3 fatty acids, glutamine, arginine are therapeutic factors that can attenuate such promote cellular immunity. The question is whether immunonutrition (IN) during CCRT reduces improves the immune function in patients with esophageal squamous cell carcinoma (ESCC). Seventy-one locally advanced ESCC being treated (5-FU cisplatin) were randomized into 2 groups. IN group received...
241 Background: At interim analysis of the phase 3, randomized, double-blind KEYNOTE-590 (NCT03189719) study, 1L pembrolizumab (pembro) + chemotherapy (chemo) vs chemo alone provided superior OS, PFS, and ORR with a manageable safety profile in patients (pts) untreated, advanced/unresectable or metastatic adenocarcinoma esophageal squamous cell carcinoma (ESCC) Siewert type 1 esophagogastric junction (EGJ). We report efficacy, safety, health-related quality life (HRQoL) results an additional...
This study aimed to evaluate acute major toxicities, the response rate, 3-year overall survival and progression-free rate of locally advanced nasopharyngeal carcinoma patients on concurrent carboplatin chemoradiotherapy followed by 5-fluorouracil. A prospective fifty diagnosed with received conventional radiation therapy a total dose 6600-7000 cGy in 6-7 weeks chemotherapy three cycles during radiotherapy, adjuvant using plus 5-fluorouracil for two cycles. Weight loss mucositis were most...